CAPSOVISION INC (CV)
Health Care · Capsule endoscopy and GI diagnostic imaging · NASDAQ
CapsoVision commercializes AI-powered capsule endoscopy systems with panoramic imaging for small bowel and emerging colon diagnostics, targeting gastroenterologists globally.
What CAPSOVISION INC does
CapsoVision is a global medical technology company that develops and commercializes capsule endoscopy solutions for visualizing and diagnosing abnormalities of the GI tract. The company's core product, CapsoCam Plus, is a single-use capsule endoscope with panoramic imaging for small bowel visualization, supported by cloud-based software (CapsoCloud and CapsoView) and AI-assisted pathology detection tools. CapsoVision is expanding its portfolio with CapsoCam Colon, a next-generation capsule incorporating 3D sensing for polyp detection and measurement, currently in late-stage FDA review.
Themes: capsule endoscopy / GI diagnostics, AI-assisted pathology detection, cloud-based medical imaging, colorectal polyp detection, small bowel visualization, pancreatic cancer screening
Fundamentals
- Price$6.02 as of 2026-08-21 close
- Market cap$301M as of 2026-08-21
- 1-year return+51.3% 2025-08-21 close $3.98 → 2026-08-21 close $6.02
- P/En/a negative earnings
- Net margin-198.9% as of 2026-08-24
- Gross margin+51.7% as of 2026-08-24
- ROE-184.2% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+0.3% as of 2026-08-24
- Beta-1.62 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How CV compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CAPSOVISION INC looks technically
CAPSOVISION INC (CV) is trading 9.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average has held above its 200-day average for at least 78 trading days — a long-sustained "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 6 trading days ago (its momentum flipped negative). It made a new 20-day low about 2 trading days ago. It is 60.8% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 9.4% below its 200-day average, the long-term trend line — a long-term downtrend | -9.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $6.67 | $6.67 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.64 | $6.64 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Since the 50/200 cross | its 50-day average has held above its 200-day average for at least 78 trading days — a long-sustained "golden cross", a bullish long-term signal | at least 78 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend | 13.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30) | 39.5 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($5.86 to $7.33) — its "stochastic" reading is 11 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 10.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 6 trading days ago (its momentum flipped negative) | 6 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $15.37 | $15.37 |
|---|---|---|
| From the 52-week high | it is 60.8% below its 52-week high (its highest price of the past year) | -60.8% |
| Above the 52-week low | it is 74.5% above its 52-week low (its lowest price of the past year) | +74.5% |
| Below the 52-week high | it is 60.8% below its highest point of the past year | 60.8% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 38 trading days ago | 38 sessions |
| All-time high | its highest closing price on record is $15.37 (set on 2025-12-11) | $15.37 |
| Given back of the 52-week move | over the past year its closes ranged ($3.56 to $14.42), and it has given back well over two thirds of its rise from last year’s low — 77% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.36 to $7.71. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 77.3% |
| From the all-time high | it is 60.8% below its all-time high | -60.8% |
| Nearest price level | it is trading 5.8% above a support level at $5.67 — a price it turned at three times since 2025-11-13, most recently on 2026-07-07. Since 2025-07-02 it has 4 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -5.8% |
| All-time low | its lowest closing price on record is $3.45 (set on 2025-09-08) | $3.45 |
| Above the all-time low | it is 74.5% above its all-time low | +74.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 77% of it) | 23rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4002 between its high and its low — about 6.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4002 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $5.94 and $7.27 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $5.94 – $6.60 – $7.27 |
| Typical daily range (% of price) | its price moves about 6.7% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.7% |
| Stretch from the 200-day average | it is trading 1.6 daily ranges below its 200-day average price (9.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.6 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.70× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.7% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.7% |
|---|---|---|
| Open gap | it gapped 4.3% below the previous close 5 sessions ago and has not traded back through the level it left behind at 6.79 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -4.3% |
| Gap filled | a 2.8% gap down opened on 2026-08-17 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 16.6 percentage points (the stock lost 14.2% while the market gained 2.3%) | -16.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 14.2 percentage points (the stock lost 11.1% while the market gained 3.1%) | -14.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 17.6 percentage points (the stock gained 28.6% while the market gained 11.1%) | +17.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 30.8 percentage points (the stock gained 51.3% while the market gained 20.5%) | +30.8% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 8.7% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.0% of the share price, which is taken to mean a barrier that gives way easily. | -8.7% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 7% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $6.48 — a volume-weighted average of daily closes over 150 sessions, not a true tick-by-tick VWAP. | -7.1% |
|---|
Price levels it has turned at before
CV last closed at $6.02 on 2026-08-21. Since 2025-07-02 it has turned at 4 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.67 | Support | 5.8% below the last close | turned there three times · 2025-11-13 to 2026-07-07 |
| $6.37 | Resistance | 5.9% above the last close | turned there twice · 2026-06-17 to 2026-08-05 |
| $5.02 | Support | 16.6% below the last close | turned there three times · 2025-10-03 to 2026-03-18 |
| $7.12 | Resistance | 18.3% above the last close | turned there twice · 2026-01-16 to 2026-07-22 |
| $4.53 | Support | 24.8% below the last close | turned there twice · 2025-10-30 to 2026-02-20 |
| $7.73 | Resistance | 28.3% above the last close | turned there four times · 2026-05-04 to 2026-07-01 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · trendless / choppy (low ADX) · beating the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 1 analyst
- Mean price target$10.00 range $10.00 – $10.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Dependence on FDA clearances for pipeline products (CapsoCam Colon and AI-enhanced CapsoCam Plus); regulatory delays or denials could materially impact growth and commercialization timelines.","Significant operating losses and negative net margins (-198.87%) with minimal revenue growth (0.32% YoY); company is unprofitable and dependent on capital to fund R&D and commercialization efforts.","Supply chain concentration risk; manufacturing relies on component suppliers and assembly partners in Asia (Taiwan and Japan), creating exposure to geopolitical disruption and supply constraints."]
What changed in the latest 10-Q
AI-assisted comparison of CV's 10-Q filed 2026-05-14 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing added reference to 'Annual Report on Form 10-K for the year ended December 31, 2025' as comparative document
- Newer filing specifies CapsoCam Plus usage in 'over 167,000 patients' as of March 31, 2026
- Newer filing added details on FDA meeting in December 2025 discussing panoramic image processing, study design, sample size, and primary endpoint
- Newer filing states decision to 'not further pursue the submission and approval for the First-Generation Product'
- Newer filing mentions Second-Generation Product features: 'improved imaging quality and increased field of review with use of AI and better lens'
- Newer filing states second arm pivotal study expanded to 'approximately 800 patients at up to 20 sites' with 'over 600 patients enrolled' as of report date
- Newer filing specifies expected 510(k) submission for Second-Generation Product in 'third quarter of 2026'
- Newer filing states AI clinical study 510(k) submission occurred in December 2025 with FDA feedback received in March 2026 and responses submitted in April 2026
- Newer filing states expectation of FDA clearance for AI product 'by the middle of 2026'
- Newer filing added details on Breakthrough Device Designation rejection in January 2026 citing lack of specific diagnostic criteria definition
- Newer filing describes initiation of pancreatic cancer detection study in May 2026 with expected enrollment of 'up to 140 patients'
- Newer filing states 'first patient has been enrolled' in pancreatic study as of May 11, 2026
- Newer filing updated accumulated deficit to '$162.7 million' as of March 31, 2026
- Newer filing identifies largest international shipping destinations as 'France, Germany, and Saudi Arabia' for three months ended March 31, 2026
- Newer filing changed 'Cloud solution' to 'cloud-based solution'
- Removed:
- Older filing reference to prospectus filed July 3, 2025 and Registration Statement (File No. 333-287148) removed
- Older filing reference to 'for the year ended December 31, 2024' removed
- Removed statement about founding in 2005 and headquarters location (relocated in newer text)
- Removed 'Saudi Arabia' from largest international shipping destinations; replaced with 'Canada' in older filing
- Removed reference to accumulated deficit of '$148.3 million' as of September 30, 2025
- Removed references to Kevin Lundquist stepping down as CFO in late August 2025
- Removed reference to David Garcia joining as Senior VP of Finance on November 3, 2025
- Removed reference to Rebecca Petersen's retirement effective October 15, 2025
- Removed reference to Keri Jorgenson's promotion to Director of Clinical Operations
- Removed 'review' after 'First-Generation Product' phrase in newer filing
- Removed details about second arm study involving 'approximately 250 patients enrolled at up to 10 sites'
- Removed statement about FDA submission planned for 'second quarter of 2026' for Second-Generation Product
- Removed statement about goal of obtaining FDA clearance 'in the fourth quarter of 2026'
- Removed statement about plan to submit 510(k) application 'by year end 2025' for AI study
- Removed reference to 'approximately 6 months' FDA review timeline
- Removed reference to resource constraints from third-party biostatistician
- Removed reference to contracting with additional biostatistical consulting group
- Removed detailed explanation of Breakthrough Device Designation benefits
- Removed July 15, 2025 Canon Inc. development agreement details regarding CMOS image sensors
- Reworded:
- Reordered sentence structure: founding date and headquarters moved earlier in overview section in newer filing
- Changed largest international destinations from 'France, Germany, and Canada' to 'France, Germany, and Saudi Arabia' for specified period
- Replaced 'Cloud solution' with 'cloud-based solution' in newer filing
- Older filing stated 'began the second arm' in Q3 2025; newer filing presents decision to 'not further pursue' First-Generation and 'prioritize resources' for Second-Generation as past decision
- Older filing described ongoing FDA engagement for First-Generation; newer filing states formal decision to abandon First-Generation approach
- AI study timeline changed from 'by year end 2025' (older) to 'December 2025' submission with 'March 2026' FDA feedback and 'middle of 2026' expected clearance (newer)
- Notes:
- Older filing is truncated at end (cuts off mid-sentence in final paragraph), limiting complete comparison of closing statements
- Comparison spans different fiscal periods (Q3 2025 ended September 30 in older filing vs. Q1 2026 ended March 31 in newer filing), so some changes reflect time progression rather than substantive disclosure revisions
Risk Factors
- Added:
- Summary risk factor bullet added: 'Any failure or defect in our GI-tract capsule endoscopy solution could harm our reputation, expose us to liability, and reduce our sales.' (moved from later position in older filing)
- Summary risk factor bullet added: 'We face substantial geopolitical and trade risks (including a possible trade war and imposition of tariffs and supply chain interruptions) and natural disaster risks associated with our business operations in Asia (particularly Taiwan and Japan).' (moved from later position in older filing)
- Summary risk factor bullet added: 'We may face expansion risks when expanding in existing and entering into new foreign markets.' (moved from later position in older filing)
- Summary risk factor bullet added: 'The clinical results of our various clinical studies (including those for our CapsoCam Colon capsule) may not be released in any peer-reviewed publications.' (moved from later position in older filing)
- Removed:
- Older summary risk factor: 'We may not obtain or may experience delays in obtaining 510(k) clearance for our initial CapsoCam Colon capsule endoscopy solution or our planned second generation of our CapsoCam Colon solution (with improved optics and other components), which would adversely impact our ability to commercialize this product and generate related revenue.' - condensed and revised in newer filing
- Reworded:
- Going concern footnote reference updated from 'Our audited financial statements for the year ended December 31, 2024 and our unaudited financial statements for the nine months ended September 30, 2025' to 'Our Quarterly Report, our unaudited financial statements for the three months ended March 31, 2026 and our audited financial statements for the year ended December 31, 2025' (reflecting new quarterly reporting period)
- CapsoCam Colon expected revenue timing changed from 'fourth quarter of 2026' to 'middle of 2027' based on anticipated FDA clearance timing
- Reference to net loss periods changed from 'For the years ended December 31, 2023 and December 31, 2024, and for the nine months ended September 30, 2025' to 'For the three months ended March 31, 2026 and March 31, 2025'
- Accumulated deficit amount updated from '$148.3 million' as of September 30, 2025 to '$162.7 million' as of March 31, 2026
- Quarterly net losses updated from nine-month/annual periods to quarterly: '$7.0 million' (Q1 2026) and '$5.4 million' (Q1 2025)
- Risk factor summary introduction language changed from 'Our business is subject to numerous risks and uncertainties. This summary provides an overview of such risks.' to 'Below is a summary of the principal risks and uncertainties that make an investment in our securities speculative or risky.'
- Risk factor summary qualifier updated to include 'Importantly, this summary does not address all of the risks that we face.'
- 510(k) clearance risk factor reorganized: removed separate bullet for initial CapsoCam Colon clearance; consolidated into single bullet focusing on second generation with improved optics
- Order of summary risk factors reorganized with different sequence of bullet points
- Notes:
- The newer filing section provided is truncated and does not include the complete 'Business and Industry Risk Factors' section heading and text
- Comparison limited to the portions of text provided; full assessment of all changes may require complete sections
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
3 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days3 buys ($1M) · 1 sell ($8587) — 1 buying, 1 selling insiders
- Last 180 days3 buys ($1M) · 1 sell ($8587) — 1 buying, 1 selling insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-17. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CV's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding CV as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 1,561,623
- Reported value $11,384,231
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CV had 1,913,811 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CV had 3.82% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 21.05 days to cover at the same settlement.
- Reported short interest (shares) 1,913,811
- Short interest (% of shares outstanding) 3.82%
- Prior settlement (shares) 2,109,923
- Reported change -9.29%
- Days to cover (reported) 21.05
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Intromedic (pillcam/capsule endoscopy)
- Boston Scientific (capsule endoscopy / GI diagnostics)
- Medtronic (endoscopy and GI diagnostics)
- Pentax Medical (endoscopy systems)
- Olympus (endoscopy and medical imaging)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CV vs…
Frequently asked questions
What does CAPSOVISION INC (CV) do?
CapsoVision is a global medical technology company that develops and commercializes capsule endoscopy solutions for visualizing and diagnosing abnormalities of the GI tract. The company's core product, CapsoCam Plus, is a single-use capsule endoscope with panoramic imaging for small bowel visualization, supported by cloud-based software (CapsoCloud and CapsoView) and AI-assisted pathology detection tools.
What sector is CAPSOVISION INC (CV) in?
CAPSOVISION INC (CV) is classified in the Health Care sector. Its industry is Capsule endoscopy and GI diagnostic imaging. It trades on NASDAQ.
Who are CAPSOVISION INC's (CV) competitors?
Notable peers of CAPSOVISION INC (CV) include Intromedic (pillcam/capsule endoscopy), Boston Scientific (capsule endoscopy / GI diagnostics), Medtronic (endoscopy and GI diagnostics), Pentax Medical (endoscopy systems) and Olympus (endoscopy and medical imaging). This peer set is informational only — not financial advice.
Is CAPSOVISION INC (CV) overbought or oversold right now?
CAPSOVISION INC (CV) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 40, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CV come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.